[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oral-cavity-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oral-cavity-neoplasm":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100153436","wide-field-and-high-resolution-in-vivo-imaging-in-visualizing-lesions-in-patients-with-oral-neoplasia-undergoing-surgery-100153436",false,"NCT01269190","Wide-Field and High Resolution In Vivo Imaging in Visualizing Lesions in Patients With Oral Neoplasia Undergoing Surgery","Wide-Field and High Resolution In Vivo Imaging of Oral Neoplasia Using Topical Fluorescent Dyes: A Feasibility Study","Inclusion Criteria:\n\n* Adult subjects with oral lesions undergoing surgical resection (i.e., only patients who are scheduled to undergo a surgery of the head \\& neck area to remove or biopsy oral lesions will be eligible to participate in the study); patients with previous treatment are eligible\n* Ability to understand and the willingness to sign a written informed consent document (ICD)\n\nExclusion Criteria:\n\n* Known allergy to proflavine or acriflavine\n* Pregnant or nursing females\n* The participant will be excluded from participation in another clinical research trial (i.e., a trial in which an agent is actively administered to the study subject), while being imaged (on active treatment) on this protocol","ALL","18 Years",{"count":19,"type":20},275,"ESTIMATED","INTERVENTIONAL",[23],"NA","This clinical trial studies wide-field and high resolution in vivo imaging in visualizing lesions in patients with abnormal or uncontrolled oral cell growth (neoplasia) undergoing surgery. Diagnostic procedures, such as wide-field and high resolution in vivo imaging, are devices that let researchers look at a wide area of the lining of the mouth by shining different colors inside the mouth and taking pictures and this may help doctors to decide if a mouth lesion has a high risk of being pre-cancerous or cancerous.",[26],"Oral Cavity Neoplasm","RECRUITING","2026-02-09",{"date":30,"type":31},"2026-02-11","ACTUAL",{"date":33,"type":31},"2010-12-30",{"date":35,"type":20},"2028-12-31",{"name":37,"class":38},"M.D. Anderson Cancer Center","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":39},"100623704","phase-2-neoadjuvant-chemoimmunotherapy-camrelizumab--paclitaxel--carboplatin-for-resectable-hnscc-100623704","NCT07400094","Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC","Prospective Non-Randomized Phase II Study of Neoadjuvant Camrelizumab Combined With Paclitaxel and Carboplatin in Patients With Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity and Larynx (Stage III-IVA)","NeoCamre-HN","Inclusion Criteria:\n\n* Histologically confirmed squamous cell carcinoma of the oral cavity and\u002For larynx, Stage III-IVA (cT1-2N1-2M0, cT3-4aN0-2M0)\n* Resectable disease planned for surgical treatment\n* Age 18-75 years\n* No prior antitumor therapy for the current diagnosis\n* Tumor sample available for PD-L1 expression assessment\n* No other malignancies in anamnesis (except basal cell carcinoma of skin and carcinoma in situ of cervix)\n* Absence of comorbidities preventing systemic chemotherapy and immunotherapy\n\nExclusion Criteria:\n\n* Patient refusal to undergo planned treatment\n* Protocol violations not related to medical indications","75 Years",{"count":50,"type":20},50,[52],"PHASE2","This phase II study evaluates the efficacy and safety of neoadjuvant chemoimmunotherapy consisting of camrelizumab (PD-1 inhibitor), paclitaxel, and carboplatin in patients with resectable locally advanced (Stage III-IVA) squamous cell carcinoma of the oral cavity and\u002For larynx.\n\nFifty patients will receive 3 cycles of therapy (camrelizumab 200 mg IV, paclitaxel 175 mg\u002Fm2 IV, carboplatin AUC6 IV, Day 1 every 21 days) followed by radical surgery 4-6 weeks later. Patients are then stratified to risk-adapted adjuvant therapy based on pathological findings (radiation or chemoradiation with cisplatin if adverse features present).\n\nThe primary endpoint is the pathological complete response (pCR) rate and major pathological response (MPR, \\\u003C10% viable tumor cells) rate at surgery. Secondary endpoints include objective response rate (ORR) by imaging (MRI\u002FPET-CT), correlation of PET-CT metabolic response with pathological response, proportion requiring adjuvant chemoradiation, and 3-year event-free survival compared to historical controls.\n\nStudy period: 2026-2029.",[55,56,26],"Squamous Cell Carcinoma of Head and Neck","Laryngeal Neoplasms",[58,59,60,61,62,63,64],"Head and Neck Squamous Cell Carcinoma","Neoadjuvant Therapy","Camrelizumab","Paclitaxel","Carboplatin","Pathological Complete Response","PD-1 Inhibitor","NOT_YET_RECRUITING","2026-02-03",{"date":68,"type":31},"2026-02-10",{"date":70,"type":20},"2026-02",{"date":72,"type":20},"2029-02",{"name":74,"class":38},"National Medical Research Radiological Centre of the Ministry of Health of Russia"]